Helix B surface peptide administered after insult of ischemia reperfusion improved renal function, structure and apoptosis through beta common receptor/erythropoietin receptor and PI3K/Akt pathway in a murine model

Experimental Biology and Medicine

Volumn 238, Issue 1, 2013, Pages 111-119

  Yang, Cheng ^a,b   Zhao, Tian ^a,b   Lin, Miao ^a,b   Zhao, Zitong ^a,b   Hu, Linkun ^c   Jia, Yichen ^a,b   Xue, Yinjia ^a,b   Xu, Ming ^a,b   Tang, Qunye ^a,b   Yang, Bin ^d,e,f   Rong, Ruiming ^a,b   Zhu, Tongyu ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Key Laboratory of Organ Transplantation   (China)

^c SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e NANTONG UNIVERSITY   (China)

^f LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Beta common receptor Experimental; Helix B surface peptide; Renal ischemia reperfusion injury; Signal transduction

Indexed keywords

BETA ADRENERGIC RECEPTOR; CASPASE 3; CASPASE 9; CREATININE; ERYTHROPOIETIN RECEPTOR; HELIX B SURFACE PEPTIDE; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BETA SHEET; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY; SCORING SYSTEM; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ERYTHROPOIETIN; ISCHEMIA; KIDNEY; MALE; MICE; MICE, INBRED BALB C; ONCOGENE PROTEIN V-AKT; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ERYTHROPOIETIN; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84875604065     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.012185     Document Type: Article

References (27)

1. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-32
2. Ishii Y, Sawada T, Murakami T, Sakuraoka Y, Shiraki T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant 2011;26:1157-62
3. Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther 2010;128:445-59
4. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010;36:537-49
5. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470-80
6. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12
7. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010;29:86-92
8. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925-30
9. Su KH, Shyue SK, Kou YR, Ching LC, Chiang AN, Yu YB, Chen CY, Pan CC, Lee TS. Beta common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011;226:3330-9
10. Boehle AS, Kurdow R, Boenicke L, Schniewind B, Faendrich F, Dohrmann P, Kalthoff H. Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg 2002;387:234-9
11. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056-63
12. Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci USA 2010;107:14357-62
13. Toronyi E. [Role of apoptosis in the kidney after reperfusion]. Orv Hetil 2008;149:305-15
14. Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 2008;40:3279-88
15. van den Eijnden MM, Leuvenink HG, Ottens PJ, t Hart NA, van Oeveren W, Morariu AM, van Goor H, Ploeg RJ. Effect of brain death and non-heart-beating kidney donation on renal function and injury: an assessment in the isolated perfused rat kidney. Exp Clin Transplant 2003;1:85-95
16. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 2008;10:601-19
17. Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009;119:1275-85
18. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004;66:500-6
19. Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011;17:194-200
20. Neri LM, Borgatti P, Capitani S, Martelli AM. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta 2002;1584:73-80
21. Xie L, Zheng X, Qin J, Chen Z, Jin Y, Ding W. Role of PI3-kinase/Akt signalling pathway in renal function and cell proliferation after renal ischaemia/reperfusion injury in mice. Nephrology (Carlton) 2006;11:207-12
22. Williams DL, Ozment-Skelton T, Li C. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 2006;25:432-9
23. Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 2004;109:3042-9
24. Wang JK, Yu LN, Zhang FJ, Yang MJ, Yu J, Yan M, Chen G. Postconditioning with sevoflurane protects against focal cerebral ischemia and reperfusion injury via PI3K/Akt pathway. Brain Res 2010;1357:142-51
25. Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C. The delayed administration of pHBSP, a novel non-erythropoietic analogue of erythropoietin, attenuates acute kidney injury. Mol Med 2012;18:719-27
26. Xu X, Cao Z, Cao B, Li J, Guo L, Que L, Ha T, Chen Q, Li C, Li Y. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Surgery 2009;146:506-14
27. Caron A, Desrosiers RR, Beliveau R. Kidney ischemia-reperfusion regulates expression and distribution of tubulin subunits, beta-actin and rho GTPases in proximal tubules. Arch Biochem Biophys 2004;431:31-46